Here is the full article of a recent phase 3 trial comparing methtotrexate with tofacitinib (where do they get these names ? :) )
It seems to hold some promise especially as it is targetting a different area of the T cell functionality.
It may also have some relevance to SS especially extra glandular symptoms?
Slight downside is increased infections ude to immuno suppression.
http://www.nejm.org/doi/full/10.1056/NEJMoa1310476#Discussion=&t=articleTop